Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 04 04:00PM ET
8.73
Dollar change
-0.36
Percentage change
-3.96
%
Index- P/E- EPS (ttm)-4.51 Insider Own21.56% Shs Outstand10.52M Perf Week-10.00%
Market Cap111.63M Forward P/E- EPS next Y-1.86 Insider Trans0.00% Shs Float10.24M Perf Month3.80%
Income-43.02M PEG- EPS next Q-0.51 Inst Own7.73% Short Float13.27% Perf Quarter4.55%
Sales0.00M P/S- EPS this Y72.73% Inst Trans-20.57% Short Ratio5.61 Perf Half Y61.97%
Book/sh-0.15 P/B- EPS next Y-9.28% ROA-308.78% Short Interest1.36M Perf Year41.72%
Cash/sh0.31 P/C27.91 EPS next 5Y- ROE-453.01% 52W Range4.53 - 22.49 Perf YTD-53.32%
Dividend Est.- P/FCF- EPS past 5Y-126.41% ROI- 52W High-61.18% Beta1.71
Dividend TTM- Quick Ratio1.24 Sales past 5Y0.00% Gross Margin- 52W Low92.72% ATR (14)0.70
Dividend Ex-Date- Current Ratio1.24 EPS Y/Y TTM-26.44% Oper. Margin0.00% RSI (14)47.61 Volatility6.16% 8.58%
Employees6 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price40.17
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q58.33% Payout- Rel Volume0.62 Prev Close9.09
Sales Surprise- EPS Surprise29.93% Sales Q/Q- EarningsAug 15 BMO Avg Volume242.06K Price8.73
SMA20-2.21% SMA501.74% SMA200-3.93% Trades Volume149,246 Change-3.96%
Date Action Analyst Rating Change Price Target Change
Oct-25-24Upgrade Maxim Group Hold → Buy $25
Dec-29-23Initiated Canaccord Genuity Buy $36
Jul-07-21Reiterated Maxim Group Buy $45 → $150
Oct-31-24 08:00AM
Oct-22-24 08:00AM
Oct-17-24 10:52AM
Oct-15-24 08:00AM
Oct-03-24 08:30AM
08:30AM Loading…
08:30AM
Oct-02-24 08:30AM
Sep-30-24 08:00AM
Sep-05-24 08:00AM
Aug-15-24 07:00AM
Aug-06-24 09:00AM
08:30AM
08:00AM
Aug-05-24 08:00AM
Jul-24-24 08:00AM
08:00AM Loading…
Jul-16-24 08:00AM
Jul-09-24 08:00AM
Jul-03-24 12:53PM
12:21PM
09:10AM
Jul-02-24 04:45PM
08:00AM
Jun-27-24 08:00AM
Jun-26-24 08:00AM
Jun-25-24 08:00AM
Jun-18-24 08:00AM
Jun-17-24 08:00AM
Jun-11-24 08:00AM
Jun-05-24 08:00AM
May-28-24 09:55AM
07:30AM Loading…
May-21-24 07:30AM
May-13-24 01:53PM
07:30AM
May-09-24 07:30AM
May-06-24 07:30AM
Apr-30-24 10:17AM
Apr-29-24 02:54PM
12:12PM
10:51AM
10:20AM
10:10AM
Apr-24-24 09:55AM
Apr-08-24 09:55AM
Apr-02-24 12:53PM
07:30AM
Apr-01-24 08:00AM
Mar-21-24 09:55AM
Mar-20-24 07:30AM
Mar-18-24 08:52AM
Mar-06-24 03:33PM
Feb-27-24 08:00AM
Feb-26-24 01:14PM
Feb-14-24 07:30AM
Feb-12-24 04:06PM
Jan-30-24 08:00AM
Jan-24-24 08:00AM
Dec-21-23 04:13PM
Dec-11-23 01:00PM
Dec-05-23 07:30AM
Dec-01-23 11:12AM
07:30AM
Nov-27-23 07:30AM
Nov-08-23 05:00PM
Nov-02-23 07:30AM
Oct-31-23 08:00AM
Oct-30-23 04:48PM
04:42PM
Oct-24-23 09:13AM
Oct-18-23 08:30AM
Oct-16-23 10:47AM
Oct-13-23 12:42PM
Oct-12-23 11:29AM
11:10AM
08:02AM
Oct-11-23 09:24AM
Oct-10-23 10:24AM
Oct-09-23 09:49AM
08:52AM
Oct-06-23 12:03PM
07:30AM
Oct-04-23 11:39AM
09:32AM
09:27AM
Oct-03-23 10:45AM
09:43AM
09:11AM
Sep-29-23 12:32PM
Sep-25-23 12:06PM
12:04PM
Sep-22-23 12:00PM
11:57AM
07:57AM
Sep-21-23 01:23PM
09:35AM
Sep-20-23 10:45AM
Sep-19-23 08:30AM
Sep-18-23 01:15PM
11:39AM
Sep-13-23 11:03AM
Sep-12-23 11:56AM
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.